| Literature DB >> 33145058 |
Xingli Fan1, Yangfeng Tang1, Guanxin Zhang1, Jiajun Zhang1, Qing Xue1, Boyao Zhang1, Zhiyun Xu1, Lin Han1.
Abstract
BACKGROUND: To analyze the risk factors of chronic left ventricular dysfunction (LVD) after cardiac valve surgery.Entities:
Keywords: Heart valve surgery; atrial fibrillation; left ventricular dysfunction (LVD); pulmonary hypertension
Year: 2020 PMID: 33145058 PMCID: PMC7578501 DOI: 10.21037/jtd-20-1010
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Preoperative baseline demographic data
| Variables | LVD group (LVEF <40%, n=126) | Control group (LVEF ≥40%, n=734) | P value |
|---|---|---|---|
| Age (years) | 57±14.7 | 59±10.7 | 0.513 |
| Male (%) | 98 (77.8) | 551 (75.1) | 0.704 |
| Smoke (%) | 59 (46.8) | 347 (47.3) | 0.672 |
| Weight (kg) | 65±12.5 | 69±10.7 | 0.543 |
| Hypertension | 44 (34.9) | 293 (39.9) | 0.235 |
| Diabetes | 37 (29.4) | 190 (25.9) | 0.356 |
| CAD | 26 (20.6) | 88 (12.0) | 0.006 |
| Renal dysfunction | 12 (9.5) | 58 (7.9) | 0.482 |
| AF | 50 (39.7) | 211 (28.7) | 0.007 |
| PHT | 44 (34.9) | 183 (24.9) | 0.010 |
| NYHA classifications | |||
| I–II | 63 (50.0) | 491 (66.9) | <0.001 |
| III | 34 (27.0) | 132 (18.0) | 0.012 |
| IV | 29 (23.0) | 106 (14.4) | 0.001 |
LVD, left ventricular dysfunction; CAD, coronary artery disease; AF, atrial fibrillation; PHT, pulmonary hypertension; NYHA, New York heart association.
Echocardiography and intraoperative data
| Variables | LVD group (LVEF <40%, n=126) | Control group (LVEF ≥40%, n=734) | P value |
|---|---|---|---|
| LVEDD (mm) | |||
| Preoperative | 54±9.37 | 49±8.67 | 0.014 |
| Postoperative | 51±8.34 | 47±7.44 | 0.009 |
| LVESD (mm) | |||
| Preoperative | 38±7.32 | 32±6.98 | 0.010 |
| Postoperative | 35±6.98 | 31±9.43 | 0.017 |
| Preoperative IVST (mm) | 8.8±0.6 | 8.9±0.9 | 0.127 |
| Preoperative LVPWT (mm) | 8.9±0.5 | 9.2±0.6 | 0.092 |
| Preoperative LVEF (%) | 59±3.5 | 61±4.2 | 0.231 |
| Clamp duration (min) | 43±12.6 | 41±13.8 | 0.315 |
| CPB duration(min) | 77±11.8 | 73±12.2 | 0.298 |
| Position of valve surgery (%) | |||
| MVR | 46 (36.5) | 300 (40.9) | 0.356 |
| MVP | 30 (23.8) | 161 (21.9) | 0.640 |
| AVR | 22 (17.5) | 132 (18.0) | 0.887 |
| DVR | 28 (22.2) | 141 (19.2) | 0.432 |
| CABG (%) | 11 (8.7) | 80 (10.9) | 0.465 |
| TVP (%) | 96 (76.2) | 560 (76.3) | 0.980 |
| Radiofrequency ablation | 46 (36.5) | 289 (39.4) | 0.542 |
LVD, left ventricular dysfunction; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; IVST, interventricular septum thickness; LVPWT, left ventricular posterior wall thickness; LVEF, left ventricular ejection fraction; CPB, cardiopulmonary bypass; MVR, mitral valve replacement; MVP, mitral valvuloplasty; AVR, aortic valve replacement; DVR, double valve replacement; CABG, coronary artery bypass graft; TVP, tricuspid valvuloplasty.
Predicts of postoperative chronic left ventricular dysfunction
| Variables | OR value | 95% CI | P value |
|---|---|---|---|
| Preoperative LVEDD >55 mm | 3.242 | 1.789–7.334 | 0.018 |
| Preoperative LVESD >40 mm | 3.181 | 1.675–7.245 | 0.020 |
| Preoperative AF | 5.123 | 0.245–10.345 | 0.009 |
| Preoperative PHT | 4.994 | 0.564–11.356 | 0.012 |
| Preoperative NYHA III–IV | 2.762 | 1.022–4.234 | 0.023 |
| CPB duration | 1.185 | 0.1234–3.432 | 0.084 |
| Preoperative CAD | 3.566 | 1.973–8.013 | 0.028 |
LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; AF, atrial fibrillation; PHT, pulmonary hypertension; NYHA, New York heart association; CPB, cardiopulmonary bypass; CAD, coronary artery disease.